Klaria Pharma (Sweden) Insiders
| KLAR Stock | SEK 0.40 0.02 5.26% |
Klaria Pharma employs about 6 people. The company is managed by 7 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 0.86 employees per reported executive. Breaking down Klaria Pharma's management performance can provide insight into the firm performance.
| Hans MD Insider Chief Officer |
| Hans Richter Executive Chief Consultative |
Klaria |
Klaria Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8766) %, meaning that it generated substantial loss on money invested by shareholders. Klaria Pharma's management efficiency ratios could be used to measure how well Klaria Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Klaria Pharma Workforce Comparison
Klaria Pharma Holding is currently regarded as number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers - Specialty & Generic industry is now estimated at about 1,129. Klaria Pharma maintains roughly 6.0 in number of employees contributing less than 1% to equities under Drug Manufacturers - Specialty & Generic industry.
Klaria Pharma Holding Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Klaria Pharma Holding Price Series Summation is a cross summation of Klaria Pharma price series and its benchmark/peer.
Klaria Pharma Notable Stakeholders
A Klaria Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Klaria Pharma often face trade-offs trying to please all of them. Klaria Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Klaria Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Scott Boyer | Chief Director | Profile | |
| Hans MD | Chief Officer | Profile | |
| Hans Richter | Chief Consultative | Profile | |
| Susan Suchdev | Chief Officer | Profile | |
| Fredrik Hubinette | Chairman CTO | Profile | |
| Marc Willuhn | Manufacturing Chemistry | Profile | |
| Jesper Wiklund | Chief Officer | Profile |
About Klaria Pharma Management Performance
The success or failure of an entity such as Klaria Pharma Holding often depends on how effective the management is. Klaria Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Klaria management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Klaria management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Klaria Pharma Holding AB develops treatment methods in the therapeutic fields of migraine and pain related to cancer worldwide. Klaria Pharma Holding AB was founded in 2014 and is based in Uppsala, Sweden. Klaria Pharma is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Klaria Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Klaria Pharma Holding. Check Klaria Pharma's Beneish M Score to see the likelihood of Klaria Pharma's management manipulating its earnings.
Klaria Pharma Workforce Analysis
Traditionally, organizations such as Klaria Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Klaria Pharma within its industry.Klaria Pharma Manpower Efficiency
Return on Klaria Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 8.9M | |
| Net Loss Per Executive | 7.6M | |
| Working Capital Per Employee | 6.8M | |
| Working Capital Per Executive | 5.9M |
Additional Tools for Klaria Stock Analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.